Health-related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real-world Study by the GIMEMA.

Health-related quality of life (HRQoL) is an important goal of therapy for patients with myelodysplastic syndromes (MDS); however, little is known about HRQoL of these patients at clinical presentation. We report HRQoL profile of newly diagnosed patients with MDS across both the the International Prognostic Scoring System (IPSS) and IPSS-Revised (IPSS-R) classifications, stratified by sex and age group categories, aiming to also establish European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core30 (EORTC QLQ-C30) reference values for these patients. Analysis was based on 927 patients with a median age of 73.3 years (interquartile range, 66.0-79.2), of whom 506 and 421 with lower- and higher-risk disease respectively, according to the IPSS classification. HRQoL was assessed with the EORTC QLQ-C30 and substantial differences by age groups and sex, between and within lower- and higher-risk disease categories were observed. For example, within higher-risk disease patients, the youngest group (ie, 30-59 years) tended to report clinically meaningful worse outcomes across various functional and symptom domains compared with older age groups. We also developed 2 regression models allowing for the prediction of EORTC QLQ-C30 reference scores for patients classified according to either the IPSS or the IPSS-R. Investigation of prevalence rates for clinically important problems and symptoms at diagnosis revealed a substantial burden of the disease with >50% of patients reporting clinically important problems with physical functioning and dyspnea in both lower- and higher-risk disease. Our findings may help to enhance the interpretation of HRQoL outcomes in future MDS studies and to better contextualize HRQoL data from routine practice settings.

Informations de copyright

Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.

Déclaration de conflit d'intérêts

FE: Consultancy or advisory role for AbbVie, Incyte, Janssen, and Syros, outside the submitted work. CF: Research support da Amgen, Sanofi e BMS. ML: Advisory boards: Abbvie, Novartis, MSD, Gilead, Jazz Pharma, Grifols, Sanofi, outside the submitted work. GAP: Speaker fees from AbbVie, Bristol Myers Squibb (BMS), Incyte, and Novartis, has participated in advisory boards of Abbvie, AOP Orphan Pharmaceuticals, AstraZeneca, BMS, GSK, Morphosys, and Novartis, and received support for attending meetings from Abbvie, BeiGene, BMS, Jannsen, Novartis. UP: Honoraria and research support: Geron, BMS, Amgen, Abbvie, Curis, Jazz. AR: Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Novartis, Sobi, Alexion. Participation on Advisory Board: Novartis, Sobi, Alexion, BMS. RS: Celgene/BMS (Advisory board); Celgene/BMS (Honoraria); Celgene/BMS (Research funding). MV: Honoraria from Amgen, Incyte, Novartis, Dephaforum Srl, Abbvie, and Astrazeneca. Advisory board for Amgen, outside the submitted work. All the other authors have no conflicts of interest to disclose.